Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Xuanqian Xie, Alexis K. Schaink, Chengyu Gao, Olga Gajic-Veljanoski, Wendy J. Ungar & Andrei Volodin. (2023) Evaluating the correlations of cost and utility parameters from summary statistics for probabilistic analysis in economic evaluations. Expert Review of Pharmacoeconomics & Outcomes Research 23:8, pages 901-909.
Read now
Read now
Jean-François Yale, Beatrice Osumili, Beth D. Mitchell, Barnaby Hunt, Gurjeev Sohi, Mark Jeddi, Donna Mojdami & William J. Valentine. (2022) Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis. Journal of Medical Economics 25:1, pages 238-248.
Read now
Read now
LK Billings, M Mocarski, A Basse, B Hunt, WJ Valentine & E Jodar. (2019) Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA. ClinicoEconomics and Outcomes Research 11, pages 271-282.
Read now
Read now
Michael Dempsey, Michelle Mocarski, Jakob Langer & Barnaby Hunt. (2018) Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of Medical Economics 21:11, pages 1110-1118.
Read now
Read now
Wendy S. Lane, James Weatherall, Jens Gundgaard & Richard F. Pollock. (2018) Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. Journal of Medical Economics 21:2, pages 144-151.
Read now
Read now
Jieruo Liu, Rosa Wang, Michael L. Ganz, Yurek Paprocki, Doron Schneider & James Weatherall. (2018) The burden of severe hypoglycemia in type 1 diabetes. Current Medical Research and Opinion 34:1, pages 171-177.
Read now
Read now
Shraddha Chaugule & Claudia Graham. (2017) Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective. Journal of Medical Economics 20:11, pages 1128-1135.
Read now
Read now
B. Hunt, M. Mocarski, W. J. Valentine & J. Langer. (2017) Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. Journal of Medical Economics 20:7, pages 663-670.
Read now
Read now
Timothy S. Bailey & Jenine Y. Stone. (2017) A novel pen-based Bluetooth-enabled insulin delivery system with insulin dose tracking and advice. Expert Opinion on Drug Delivery 14:5, pages 697-703.
Read now
Read now
Charles Shaefer, Debbie Hinnen & Christopher Sadler. (2016) Hypoglycemia and diabetes: increased need for awareness. Current Medical Research and Opinion 32:9, pages 1479-1486.
Read now
Read now
Javier Escalada, Laura Liao, Chunshen Pan, Hongwei Wang & Mohan Bala. (2016) Outcomes and healthcare resource utilization associated with medically attended hypoglycemia in older patients with type 2 diabetes initiating basal insulin in a US managed care setting. Current Medical Research and Opinion 32:9, pages 1557-1565.
Read now
Read now
Stuart Samuel, Devesh Goswami, Kenny Shum, Kristina S. Boye, Badri Rengarajan, Bradley Curtis & Sarah E. Curtis. (2015) A model of mild hypoglycemia. Current Medical Research and Opinion 31:4, pages 633-641.
Read now
Read now
Articles from other publishers (74)
Tyler J. Benning, Herbert C. Heien, Joseph R. Herges, Ana L. Creo, Alaa Al Nofal & Rozalina G. McCoy. (2023) Glucagon fill rates and cost among children and adolescents with type 1 diabetes in the United States, 2011–2021. Diabetes Research and Clinical Practice 206, pages 111026.
Crossref
Crossref
Joseph R. Herges, Jordan D. Haag, Kimberly A. Kosloski Tarpenning, Kristin C. Mara & Rozalina G. McCoy. (2023) Glucagon prescribing and prevention of hospitalization for hypoglycemia in a large health system. Diabetes Research and Clinical Practice 202, pages 110832.
Crossref
Crossref
Allyson S. Hughes, Katherine S. Chapman, Huyen Nguyen, Jingwen Liu, Jeoffrey Bispham, Melissa Winget, Stuart A. Weinzimer & Wendy A. Wolf. (2023) Severe Hypoglycemia and the Use of Glucagon Rescue Agents: An Observational Survey in Adults With Type 1 Diabetes. Clinical Diabetes 41:3, pages 399-410.
Crossref
Crossref
Christina Tzogiou, Simon Wieser, Klaus Eichler, Maria Carlander, Sima Djalali, Thomas Rosemann & Michael Brändle. (2023) Incidence and costs of hypoglycemia in insulin-treated diabetes in Switzerland: A health-economic analysis. Journal of Diabetes and its Complications 37:6, pages 108476.
Crossref
Crossref
Joseph R. Herges, Rodolfo J. Galindo, Joshua J. Neumiller, Herbert C. Heien, Guillermo E. Umpierrez & Rozalina G. McCoy. (2023) Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021. Diabetes Care 46:3, pages 620-627.
Crossref
Crossref
Xiaotong ZhangCarrie McAdam Marx. (2023) Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States. Journal of Managed Care & Specialty Pharmacy 29:3, pages 276-284.
Crossref
Crossref
Albert ChienSneha ThanasekaranAngela GaetanoGlen ImKael WherryJanice MacLeodRobert A Vigersky. (2023) Potential cost savings in the United States from a reduction in sensor-detected severe hypoglycemia among users of the InPen smart insulin pen system. Journal of Managed Care & Specialty Pharmacy 29:3, pages 285-292.
Crossref
Crossref
Adel AlTowayan, Seetah Alharbi, Maryam Aldehami, Rand Albahli, Sama Alnafessah & Abeer M Alharbi. (2023) Awareness Level of Hypoglycemia Among Diabetes Mellitus Type 2 Patients in Al Qassim Region. Cureus.
Crossref
Crossref
Anthony L McCall, David C Lieb, Roma Gianchandani, Heidemarie MacMaster, Gregory A Maynard, M Hassan Murad, Elizabeth Seaquist, Joseph I Wolfsdorf, Robin Fein Wright & Wojtek Wiercioch. (2023) Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 108:3, pages 529-562.
Crossref
Crossref
Elizabeth Sanchez‐Rangel, Jelani Deajon‐Jackson & Janice Jin Hwang. (2022) Pathophysiology and management of hypoglycemia in diabetes. Annals of the New York Academy of Sciences 1518:1, pages 25-46.
Crossref
Crossref
Yu Wang, Ping Zhang, Hui Shao, Linda J. Andes & Giuseppina Imperatore. (2022) Medical Costs Associated With Diabetes Complications in Medicare Beneficiaries Aged 65 Years or Older With Type 1 Diabetes. Diabetes Care.
Crossref
Crossref
Pierre-Yves Benhamou, Alice Adenis, Yousra Tourki, Sylvie Pou, Stéphanie Madrolle, Sylvia Franc, Dulanjalee Kariyawasam, Jacques Beltrand, David C. Klonoff & Guillaume Charpentier. (2022) Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System. Journal of Diabetes Science and Technology, pages 193229682211285.
Crossref
Crossref
Martin, Yi Zhou, Tatsuya Takagi & Yu-Shi Tian. (2022) Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison. International Journal of Clinical Pharmacy 44:3, pages 587-598.
Crossref
Crossref
Jordan HinaharaStuart A WeinzimerEmilie R BromleyThomas F GossDavid M KendallMette Hammer. (2022) Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model. Journal of Managed Care & Specialty Pharmacy 28:4, pages 461-472.
Crossref
Crossref
Yahiya Y. Syed. (2022) Dasiglucagon in severe hypoglycemia: a profile of its use. Drugs & Therapy Perspectives 38:3, pages 105-111.
Crossref
Crossref
Alexandria Ratzki-Leewing, Bridget L Ryan, Guangyong Zou, Susan Webster-Bogaert, Jason E Black, Kathryn Stirling, Kristina Timcevska, Nadia Khan, John D Buchenberger & Stewart B Harris. (2022) Predicting Real-world Hypoglycemia Risk in American Adults With Type 1 or 2 Diabetes Mellitus Prescribed Insulin and/or Secretagogues: Protocol for a Prospective, 12-Wave Internet-Based Panel Survey With Email Support (the iNPHORM [Investigating Novel Predictions of Hypoglycemia Occurrence Using Real-world Models] Study). JMIR Research Protocols 11:2, pages e33726.
Crossref
Crossref
Ji-Yeon Lee, Young-eun Kim, Kyungdo Han, Eugene Han, Byung Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung-Hyun Ko & Yong-ho Lee. (2022) Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. JAMA Network Open 5:2, pages e220262.
Crossref
Crossref
Álvaro J. Vivas & Gabriel J. Tobón. 2022. Translational Autoimmunity. Translational Autoimmunity
425
450
.
Thomas R. Pieber, Ronnie Aronson, Ulrike Hövelmann, Julie Willard, Leona Plum-Mörschel, Kim M. Knudsen, Benedikte Bandak & Ramin Tehranchi. (2021) Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care 44:6, pages 1361-1367.
Crossref
Crossref
Lizheng Shi, Vivian Fonseca & Belinda Childs. (2021) Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. Journal of Diabetes and its Complications 35:6, pages 107916.
Crossref
Crossref
Kuixu Lan, Jian Wang, Stephen Nicholas, Qun Tang, Alison Chang & Junfang Xu. (2021) Is hypoglycemia expensive in China?. Medicine 100:5, pages e24067.
Crossref
Crossref
David C. Klonoff, Alexander Fleming & Robert Gabbay. (2019) The Need to Change Regulatory Evaluation of Hypoglycemia in Trials of Diabetes Treatments. Journal of Diabetes Science and Technology 14:6, pages 987-989.
Crossref
Crossref
João P. Ferreira, Francisco Araújo, Jorge Dores, Lèlita Santos, Estevão Pape, Mónica Reis, Árcia Chipepo, Edite Nascimento, Ana Baptista, Vanessa Pires, Carlos Marques, Adriana S. Lages, João Conceição, Pedro A. Laires, João Pelicano-Romano & Sílvia Alão. (2020) Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach. Diabetes Therapy 11:10, pages 2237-2255.
Crossref
Crossref
Esileman Abdela Muche & Banchamlak Teferi Mekonen. (2020) Hypoglycemia prevention practice and its associated factors among diabetes patients at university teaching hospital in Ethiopia: Cross-sectional study. PLOS ONE 15:8, pages e0238094.
Crossref
Crossref
Julie A. Settles, Gregg Francis Gerety, Erik Spaepen, Jeffrey Gideon Suico & Christopher J. Child. (2020) Nasal Glucagon Delivery is More Successful than Injectable Delivery: A Simulated Severe Hypoglycemia Rescue. Endocrine Practice 26:4, pages 407-415.
Crossref
Crossref
María Teresa Gil-Ibáñez & Gualberto Rodrigo Aispuru. (2020) Análisis de coste-efectividad de control glucémico con FreeStyle Libre® en pacientes diabéticos tipo 1 en atención primaria de salud de Burgos. Enfermería Clínica 30:2, pages 82-88.
Crossref
Crossref
María Teresa Gil-Ibáñez & Gualberto Rodrigo Aispuru. (2020) Cost-effectiveness analysis of glycaemic control of a glucose monitoring system (FreeStyle Libre®) for patients with type 1 diabetes in primary health care of Burgos. Enfermería Clínica (English Edition) 30:2, pages 82-88.
Crossref
Crossref
Enrique Campos-Náñez & Kurt Fortwaengler. 2020. Glucose Monitoring Devices. Glucose Monitoring Devices
51
77
.
Carmine G. Fanelli, Paola Lucidi, Geremia B. Bolli & Francesca Porcellati. 2020. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
615
652
.
Haris Hadžović, Minela Alić, Anida Dedović, Anesa Sušić, Berina Tatlić, Zerina Zorlak, Nermina Žigić, Maja Malenica & Tamer Bego. 2020. CMBEBIH 2019. CMBEBIH 2019
761
768
.
Hyder Osman Mirghani. (2019) The association between hypoglycemia and hospital use, food insufficiency, and unstable housing conditions: a cross-sectional study among patients with type 2 diabetes in Sudan. BMC Research Notes 12:1.
Crossref
Crossref
E. Lau, A. Salem, J. C. N. Chan, W. Y. So, A. Kong, M. Lamotte & A. Luk. (2019) Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Crossref
Elizabeth A. Beverly, Marilyn D. Ritholz, Rochelle G. Rennie & Sophia C. Mort. (2019) A brief interactive training with medical students improves their diabetes knowledge about hypoglycemia. BMC Medical Education 19:1.
Crossref
Crossref
Johannes Pöhlmann, Beth D. Mitchell, Sanjay Bajpai, Beatrice Osumili & William J. Valentine. (2019) Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis. Journal of Diabetes Science and Technology 13:5, pages 910-918.
Crossref
Crossref
Brianna Johnson‐Rabbett & Elizabeth R. Seaquist. (2019) Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient‐centered review. Journal of Diabetes 11:9, pages 711-718.
Crossref
Crossref
Thomas DanneJeremy PettusAndrea GiaccariBertrand CariouHelena RodbardStuart A. WeinzimerMireille BonnemaireSangeeta SawhneyJohn StewartStella WangRita de Cassia CastroSatish K. Garg. (2019) Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 21:9, pages 471-477.
Crossref
Crossref
Jakob Langer, Michael L. Wolden, Seiya Shimoda, Miki Sato & Eiichi Araki. (2019) Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy. Diabetes Therapy 10:4, pages 1347-1356.
Crossref
Crossref
Richard F. Pollock, Simon Heller, Thomas R. Pieber, Vincent Woo, Jens Gundgaard, Nino Hallén, Maria Luckevich, Deniz Tutkunkardas & Bernard Zinman. (2019) Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, Obesity and Metabolism 21:7, pages 1706-1714.
Crossref
Crossref
Carlos K. H. Wong, Thaison Tong, Garvin H. L. Cheng, Eric H. M. Tang, Praveen Thokala, Emily T. Y. Tse & Cindy L. K. Lam. (2019) Direct medical costs in the preceding, event and subsequent years of a first severe hypoglycaemia episode requiring hospitalization: A population‐based cohort study. Diabetes, Obesity and Metabolism 21:6, pages 1330-1339.
Crossref
Crossref
Yuika Ikeda, Takekazu Kubo, Eisei Oda, Machiko Abe & Shigeru Tokita. (2018) Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan. Journal of Diabetes Investigation 10:3, pages 857-865.
Crossref
Crossref
Alena Strizek, Chee-Jen Chang, Wesley Furnback, Bruce Wang, Jérémie Lebrec & Thomas Lew. (2019) The Cost of Hypoglycemia Associated With Type 2 Diabetes Mellitus in Taiwan. Value in Health Regional Issues 18, pages 84-90.
Crossref
Crossref
Volker Foos, Ke Wang, Phil McEwan, Yanlei Zhang, Ping Xin, Xiaohua Jiang, Shuli Qu, Tengbin Xiong, Raf De Moor, Mafalda Ramos, Mark Lamotte & Linong Ji. (2019) Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. Value in Health Regional Issues 18, pages 36-46.
Crossref
Crossref
Joseph Tibaldi, Martin Hadley‐Brown, Andreas Liebl, Steffen Haldrup, Viktor Sandberg, Michael L. Wolden & Helena W. Rodbard. (2019) A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism 21:4, pages 1001-1009.
Crossref
Crossref
Johan JendleJohannes PöhlmannSimona de PortuJayne Smith-PalmerStéphane Roze. (2019) Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. Diabetes Technology & Therapeutics 21:3, pages 110-118.
Crossref
Crossref
Carmine G. Fanelli, Paola Lucidi, Geremia B. Bolli & Francesca Porcellati. 2019. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
38
.
Daria J. O'Reilly, Natasha Burke, Jean-Eric Tarride, Jina Hahn & Larisa Nurkanovic. (2018) Direct Health-Care Costs and Productivity Costs Associated With Hypoglycemia in Adults With Type 1 and Type 2 Diabetes Mellitus That Participated in the Canadian Hypoglycemia Assessment Tool Program. Canadian Journal of Diabetes 42:6, pages 659-663.
Crossref
Crossref
Anthony CannonYehuda HandelsmanMichael HeileMichael Shannon. (2018) Burden of Illness in Type 2 Diabetes Mellitus. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S5-S13.
Crossref
Crossref
Pendar Farahani. (2018) Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective. International Journal of Endocrinology 2018, pages 1-7.
Crossref
Crossref
Rozalina G. McCoy, Jeph Herrin, Kasia J. Lipska & Nilay D. Shah. (2018) Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. Journal of Diabetes and its Complications 32:7, pages 693-701.
Crossref
Crossref
Wen Wan, M. Reza Skandari, Alexa Minc, Aviva G. Nathan, Aaron Winn, Parmida Zarei, Michael O’Grady & Elbert S. Huang. (2018) Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. Diabetes Care 41:6, pages 1227-1234.
Crossref
Crossref
Yingping Yi, Yawei Li, Anran Hou, Yanqiu Ge, Yuan Xu, Gang Xiong, Xinlei Yang, Stephanie Ann Acevedo, Lizheng Shi & Hua Xu. (2018) A Retrospective Cohort Study of Patients with Type 2 Diabetes in China: Associations of Hypoglycemia with Health Care Resource Utilization and Associated Costs. Diabetes Therapy 9:3, pages 1073-1082.
Crossref
Crossref
Alexandria Ratzki-Leewing, Stewart B Harris, Selam Mequanint, Sonja M Reichert, Judith Belle Brown, Jason Edward Black & Bridget L Ryan. (2018) Real-world crude incidence of hypoglycemia in adults with diabetes: Results of the InHypo-DM Study, Canada. BMJ Open Diabetes Research & Care 6:1, pages e000503.
Crossref
Crossref
Richard Hellmund, Raimund Weitgasser & Deirdre Blissett. (2018) Cost calculation for a flash glucose monitoring system for UK adults with type 1 diabetes mellitus receiving intensive insulin treatment. Diabetes Research and Clinical Practice 138, pages 193-200.
Crossref
Crossref
Manjiri Pawaskar, Edward A. Witt, Samuel S. Engel, Swapnil N. Rajpathak & Kristy Iglay. (2018) Severity of hypoglycaemia and health-related quality of life, work productivity and healthcare costs in patients with type 2 diabetes in Europe. Endocrinology, Diabetes & Metabolism 1:2, pages e00011.
Crossref
Crossref
Kurt Fortwaengler, Enrique Campos-Náñez, Christopher G. Parkin & Marc D. Breton. (2017) The Financial Impact of Inaccurate Blood Glucose Monitoring Systems. Journal of Diabetes Science and Technology 12:2, pages 318-324.
Crossref
Crossref
S Pinar Bilir, Richard Hellmund, Beth Wehler, Huimin Li, Julie Munakata & Mark Lamotte. (2018) Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden. European Endocrinology 14:2, pages 73.
Crossref
Crossref
Carmine G. Fanelli, Paola Lucidi, Geremia B. Bolli & Francesca Porcellati. 2018. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
617
654
.
Carmine G. Fanelli, Paola Lucidi, Geremia B. Bolli & Francesca Porcellati. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
38
.
Hara Kousoulakou, Magdalini Hatzikou, Varvara Baroutsou & John Yfantopoulos. (2017) Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece. Cost Effectiveness and Resource Allocation 15:1.
Crossref
Crossref
Kathryn Evans Kreider, Katherine Pereira & Blanca I. Padilla. (2017) Practical Approaches to Diagnosing, Treating and Preventing Hypoglycemia in Diabetes. Diabetes Therapy 8:6, pages 1427-1435.
Crossref
Crossref
Tim Holbrook, Yuexin Tang, Romita Das, R. Ravi Shankar, Kaan Tunceli, Jean Williams, Larry Radican, Sarah E. Holden, Chris Ll. Morgan, James Piercy & Craig J. Currie. (2017) Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study. International Journal of Clinical Practice 71:6, pages e12958.
Crossref
Crossref
Barnaby Hunt, Michelle Mocarski, William J. Valentine & Jakob Langer. (2017) IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Therapy 8:3, pages 531-544.
Crossref
Crossref
Jie MengRoman CascianoYi-Chien LeeLee SternDmitry GultyaevLiyue Tong & Brice Kitio-Dschassi. (2017) Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population. Journal of Managed Care & Specialty Pharmacy 23:4, pages 446-452.
Crossref
Crossref
Lia Bally, Hood Thabit, Harald Kojzar, Julia K Mader, Jehona Qerimi-Hyseni, Sara Hartnell, Martin Tauschmann, Janet M Allen, Malgorzata E Wilinska, Thomas R Pieber, Mark L Evans & Roman Hovorka. (2017) Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. The Lancet Diabetes & Endocrinology 5:4, pages 261-270.
Crossref
Crossref
S. Halimi. (2017) Diabète de type 2 : concilier Médecine de Précision et Primauté des Soins de Premier recours. Pas simple !. Médecine des Maladies Métaboliques 11:1, pages 5-7.
Crossref
Crossref
Cornelis A. J. van Beers & J. Hans DeVries. (2016) Continuous Glucose Monitoring. Journal of Diabetes Science and Technology 10:6, pages 1251-1258.
Crossref
Crossref
Ja Young Jeon, Se Ran Kim, Hae Jin Kim, Dae Jung Kim, Kwan-Woo Lee, Jung-Dong Lee & Seung Jin Han. (2016) Risk factors of severe hypoglycemia requiring medical assistance and neurological sequelae in patients with diabetes. Medicine 95:47, pages e5365.
Crossref
Crossref
Janet B. McGill, David Ahn, Steven V. Edelman, C. Rachel Kilpatrick & Tricia Santos Cavaiola. (2016) Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?. Advances in Therapy 33:8, pages 1267-1278.
Crossref
Crossref
Meryl Brod, Gagik Galstyan, Ambika Gopalakrishnan Unnikrishnan, Ilana Harman-Boehm, Vinay Prusty, Fernando Lavalle, Margaret McGill, Angela Murphy & Felix Puchulu. (2016) Self-Treated Hypoglycemia in Type 2 Diabetes Mellitus: Results from the Second Wave of an International Cross-Sectional Survey. Diabetes Therapy 7:2, pages 279-293.
Crossref
Crossref
Pavika J Lyngsie, Sandra Lopes & Jens Olsen. (2016) Incidence and cost of hypoglycemic events requiring medical assistance in a hospital setting in Denmark. Journal of Comparative Effectiveness Research 5:3, pages 239-247.
Crossref
Crossref
Aditya Raju, Sharash Shetty, Beilei Cai & Anna O. D’Souza. (2016) Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy. Journal of Managed Care & Specialty Pharmacy 22:5, pages 483-492.
Crossref
Crossref
Sang Youl Rhee, Soo Min Hong, Suk Chon, Kyu Jeung Ahn, Sung Hoon Kim, Sei Hyun Baik, Yong Soo Park, Moon Suk Nam, Kwan Woo Lee, Jeong-Taek Woo & Young Seol Kim. (2016) Hypoglycemia and Medical Expenses in Patients with Type 2 Diabetes Mellitus: An Analysis Based on the Korea National Diabetes Program Cohort. PLOS ONE 11:2, pages e0148630.
Crossref
Crossref
Chen-Yuan Chiu, Rong-Sen Yang, Meei-Ling Sheu, Ding-Cheng Chan, Ting-Hua Yang, Keh-Sung Tsai, Chih-Kang Chiang & Shing-Hwa Liu. (2016) Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated, AMPK-down-regulated, Akt pathway. The Journal of Pathology 238:3, pages 470-482.
Crossref
Crossref
T. Davis, A. Salahi, J. B. Welsh & T. S. Bailey. (2015) Automated insulin pump suspension for hypoglycaemia mitigation: development, implementation and implications. Diabetes, Obesity and Metabolism 17:12, pages 1126-1132.
Crossref
Crossref